Vicarious Surgical Inc. (RBOT) Cash Flow Statement
Where RBOT’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$45.1M
- Capital expenditures
- $132,000
- Free cash flow
- −$45.2M
- Returned to shareholders
- —
- Change in cash
- −$7.2M cash at year-end $3.5M
Drawn to scale: where the cash came from and how it was used. Hover for values.
RBOT operating cash flow, capex and free cash flow
RBOT cash flow trends, 2019–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$8.7M2019 | −$45.1M2025 | — | |
| Capital expenditures | $246,0002019 | $132,0002025 | −9.9%/yr | |
| Free cash flow | −$9.0M2019 | −$45.2M2025 | — | |
| Stock-based compensation | $337,0002019 | $8.1M2025 | +70.0%/yr |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
RBOT cash flow by activity
RBOT net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
RBOT cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Operating activities | |||||||
| Net income | −$50.2M | −$63.2M | −$71.1M | $5.2M | −$35.2M | −$12.9M | −$9.3M |
| Depreciation & amortization | $1.4M | $2.1M | $1.9M | $1.1M | $316,000 | $157,000 | $104,000 |
| Stock-based compensation | $8.1M | $11.9M | $13.3M | $12.3M | $3.7M | $448,000 | $337,000 |
| Change in working capital | −$4.9M | −$594,000 | −$746,000 | $3.4M | $955,000 | $232,000 | $98,000 |
| Other non-cash items | $451,000 | −$150,000 | −$5.6M | −$83.1M | −$3.1M | $0 | $64,000 |
| Cash from operating activities | −$45.1M | −$50.0M | −$62.3M | −$61.2M | −$33.3M | −$12.0M | −$8.7M |
| Investing activities | |||||||
| Capital expenditures | −$132,000 | −$180,000 | −$1.7M | −$5.4M | −$1.3M | −$120,000 | −$246,000 |
| Investments (net) | $32.3M | $6.9M | −$51.8M | −$5.4M | −$1.3M | $13.3M | −$1.6M |
| Acquisitions & other investing | $0 | $180,000 | $7.7M | $5.4M | $1.3M | $0 | $0 |
| Cash from investing activities | $32.1M | $6.9M | −$45.8M | −$5.4M | −$1.3M | $13.2M | −$1.8M |
| Financing activities | |||||||
| Share repurchases & issuance (net) | — | — | — | $542,000 | — | — | — |
| Net borrowing (repayment) | $525,000 | $0 | −$16,000 | $8.7M | $1.3M | −$48,000 | −$27,000 |
| Shares issued | $5.9M | $0 | $57.2M | $10.0M | $415,000 | $13.5M | $0 |
| Other financing | −$629,000 | $8,000 | −$12.5M | −$10.0M | $190.4M | $43,000 | $10.0M |
| Cash from financing activities | $5.8M | $8,000 | $44.7M | $9.1M | $192.2M | $13.5M | $10.0M |
| Summary | |||||||
| Net change in cash | −$7.2M | −$43.1M | −$63.4M | −$57.4M | $157.6M | $14.7M | −$559,000 |
| Cash at end of period | $3.5M | $10.7M | $53.8M | $117.1M | $174.6M | $17.0M | $2.3M |
| Free cash flow | −$45.2M | −$50.1M | −$64.0M | −$66.6M | −$34.6M | −$12.2M | −$9.0M |
| Operating cash flow / net income | — | — | — | −11.87 | — | — | — |
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | Jun '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$7.3M | −$10.5M | −$11.1M | −$13.2M | −$15.4M | −$13.9M | −$17.1M | −$15.2M | −$17.0M | −$13.1M | −$15.7M | −$15.3M |
| Depreciation & amortization | $183,000 | $291,000 | $352,000 | $413,000 | $369,000 | $542,000 | $507,000 | $537,000 | $521,000 | $525,000 | $447,000 | $441,000 |
| Stock-based compensation | $1.1M | $1.1M | $2.0M | $2.2M | $2.8M | $2.8M | $2.9M | $3.1M | $3.1M | $3.1M | $3.6M | $3.3M |
| Change in working capital | −$244,000 | −$338,632 | −$1.8M | −$3.0M | $190,000 | −$707,000 | $744,000 | $2.1M | −$2.7M | −$320,000 | −$609,000 | $1.6M |
| Other non-cash items | $1,000 | $147,632 | $5,657 | $113,641 | $280,000 | −$507,000 | $214,000 | −$1.5M | $1.6M | −$1.5M | −$5.0M | −$5.1M |
| Cash from operating activities | −$6.3M | −$9.3M | −$10.4M | −$13.5M | −$11.8M | −$11.8M | −$12.7M | −$11.0M | −$14.5M | −$11.4M | −$17.3M | −$15.1M |
| Investing activities | ||||||||||||
| Capital expenditures | −$9,000 | −$10,000 | −$116,716 | −$8 | −$5,000 | −$180,000 | −$16,000 | −$6,000 | −$10,000 | −$1.0M | −$118,000 | −$208,000 |
| Investments (net) | $4.9M | $3.0M | $9.7M | $14.8M | $4.6M | $14.4M | −$492,000 | −$7.0M | −$144,000 | $5.0M | −$644,000 | −$6.1M |
| Acquisitions & other investing | $133,000 | $0 | $79,040 | −$30,793 | $5,000 | $180,000 | $16,000 | $6,000 | $10,000 | $1.0M | $118,000 | $0 |
| Cash from investing activities | $5.1M | $3.0M | $9.7M | $14.8M | $4.6M | $14.4M | −$492,000 | −$7.0M | −$144,000 | $5.0M | −$644,000 | −$6.4M |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | — | — | — | — | — | — | $166,000 |
| Net borrowing (repayment) | −$154,000 | — | — | — | $0 | $0 | $0 | — | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $47.0M | $0 |
| Other financing | $0 | $5.7M | $25,907 | $23,935 | $16,999 | $6,000 | $0 | $0 | $2,000 | $34,000 | −$2.8M | −$4,000 |
| Cash from financing activities | −$154,000 | $5.7M | $25,907 | $23,935 | $16,999 | $6,000 | $0 | $0 | $2,000 | $34,000 | $44.2M | $162,000 |
| Summary | ||||||||||||
| Net change in cash | −$1.4M | −$595,000 | −$746,000 | $1.3M | −$7.1M | $2.7M | −$13.2M | −$18.0M | −$14.6M | −$6.3M | $26.3M | −$21.3M |
| Cash at end of period | $2.1M | $3.5M | $3.2M | $3.9M | $2.6M | $10.7M | $8.0M | $21.2M | $38.2M | $53.8M | $60.0M | $33.7M |
| Free cash flow | −$6.3M | −$9.3M | −$10.5M | −$13.5M | −$11.8M | −$12.0M | −$12.7M | −$11.0M | −$14.5M | −$12.4M | −$17.4M | −$15.3M |
| Free cash flow margin | — | — | — | — | — | −572.6% | — | — | — | −359.7% | — | — |
| Capex / revenue | — | — | — | — | — | 8.6% | — | — | — | 30.1% | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
RBOT cash generation
In fiscal 2025 (ended December 31, 2025), Vicarious Surgical generated -$45.1 million of cash from operations and spent $0.1 million on capital expenditures, leaving free cash flow of -$45.2 million. Cash and equivalents fell by $7.2 million over the year.
Related: RBOT income statement, RBOT balance sheet. See the RBOT stock overview for the latest quote and news.
RBOT cash flow FAQ
What is Vicarious Surgical's free cash flow?
Vicarious Surgical's free cash flow was -$45.2 million in fiscal 2025: -$45.1 million of operating cash flow minus $0.1 million of capital expenditures It was -$50.1 million a year earlier..
How much cash does Vicarious Surgical generate from operations?
Vicarious Surgical generated -$45.1 million of cash from operating activities in fiscal 2025.
How much does Vicarious Surgical spend on capital expenditures?
Vicarious Surgical spent $0.1 million on capital expenditures in fiscal 2025, compared with $0.2 million the year before.